Acceptance and Commitment Therapy for Mesh Injury: A HSCED Series

November 11, 2026 updated by: University of Lincoln

The Mesh Scandal: Acceptance and Commitment Therapy for Psychological Distress in Mesh Injured Women. A Hermeneutic Single-Case Efficacy Design Series.

The Patient Safety Commissioner estimates that at least 10,000 women in England have experienced significant harm resulting from vaginal mesh implants. Adverse effects resulting in psychological distress and reduced quality of life have been reported. The purpose of the study is to explore the efficacy of Acceptance and Commitment Therapy (ACT) for women with mesh injury experiencing psychological distress.

The study will use a Hermeneutic Single-Case Efficacy Design to answer the primary and secondary objectives.

Primary objective: To investigate whether ACT is an effective therapeutic intervention for women experiencing psychological distress due to mesh injury.

Secondary objectives: To determine whether there are any meaningful changes throughout the ACT intervention; whether these changes can be attributed to the ACT intervention and what factors contribute to the changes.

Participants will undergo a ten-session ACT intervention and follow-up session. A qualitative interview will be carried out to explore the change experience.

Study Overview

Detailed Description

NICE guidelines recognise the physical and psychological impact of mesh complications and recommends that psychological and psychosexual support is offered to women affected. Despite this, a therapeutic intervention for mesh complications has not yet been explored. Acceptance and Commitment Therapy (ACT) as been empirically supported for its use with populations with long term health conditions.

The study will use a hermeneutic single-case efficacy design and evaluate the process of change during the intervention. Following the ACT intervention, rich case records for each participant will be created using quantitative and qualitative data; this data will consist of demographic data, outcome measures and therapy material. The rich case records will be cross-referenced and amalgamated into an "affirmative" brief that presents evidence that the change can be attributed to the therapeutic intervention. The rich case record will also be analysed for indirect evidence to develop a "skeptic" brief, a brief presenting an alternative explanation for the therapeutic change. Both analyses will be evaluated through a presentation of both briefs, a rebuttal of the opposing brief and a summary narrative . The adjudication process will be overseen by three independent judges who will evaluate the rich case records and briefs to provide an outcome ; whether there has been a change during the therapeutic intervention and whether the therapeutic intervention was a key influence on this outcome.

Study Type

Interventional

Enrollment (Estimated)

6

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

Woman aged 18 or over.

  • Registered with a UK GP.
  • Currently under the care of or recently discharged from Nottingham or Manchester Complex Mesh Centres or have contacted their GP about mesh complications.
  • Has had surgery for Stress Urinary Incontinence (SUI) and/or Pelvic Organ Prolapse (POP) and has or have had implanted polypropylene mesh causing complications.
  • Experiencing self-reported psychological distress.
  • Able to communicate in English.
  • Has access to a device with internet access.
  • Willing and able to provide informed consent for participation in the study.
  • Willing to engage in psychological therapy.

Exclusion Criteria:

  • ACT intervention in the past twelve months due to the potential impact on the efficacy of the therapeutic intervention and to reduce cofounding variables.
  • Currently engaging in psychological therapy due to the potential impact on the efficacy of the therapeutic intervention and to reduce cofounding variables.
  • Have insufficient command of the English language due to resources and potential impact of an interpreter on mechanism of change.
  • Significant cognitive impairment.
  • Current suicidal ideation for ethical and safety reasons.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Acceptance and Commitment Therapy

Participants will receive a ten-session Acceptance and Commitment Therapy (ACT) intervention

Acceptance and commitment therapy (ACT) is a "third wave" Cognitive Behavioural Therapy that focuses on increasing psychological flexibility and acceptance of difficult experiences by undertaking value-drive actions despite psychological suffering. Psychological flexibility is developed and expanded through six core processes: acceptance, defusion, present moment awareness, self-as-context, values and committed action.

Adherence to a strict protocol is not mandated for an ACT intervention; the study will be informed by an adapted ACT intervention for chronic pain (Scott et al., 2018). The intervention will reflect the heterogenous nature of mesh injury.

The intervention will consist of ten individual weekly sessions lasting up to 60 minutes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hermeneutic Single-Case Efficacy Design - adjudication
Time Frame: Through study completion, an average of 9 months.

The adjudication process will be overseen by three independent judges who will evaluate the rich case records and briefs to provide an outcome ; whether there has been a change during the therapeutic intervention and whether the therapeutic intervention was a key influence on this outcome (Elliott et al., 2009).

Through study completion, an average of 9 months.
Psychological distress assessed using the Clinical Outcomes in Route Evaluation 10 (CORE-10; Barkham et al., 2013)
Time Frame: From baseline to the end of treatment, up to 16 weeks.

10-item measure designed to measure common presentations of psychological distress. The minimum value is 0 and the maximum value is 40. A higher score indicates severe distress.

From baseline to the end of treatment, up to 16 weeks.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mesh symptoms impact on quality of life assessed using the International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol; Kelleher et al., 1997)
Time Frame: From baseline to the end of treatment, up to 16 weeks.

20-item measure designed to measure the physical, emotional, social, and practical impact of urinary symptoms. Measure adapted to assess "mesh problem" instead of "urinary problem" (Brown, 2020). The minimum value is 0 and the maximum value is 76. A higher score indicates greater impact on quality of life.

From baseline to the end of treatment, up to 16 weeks.
Psychological flexibility assessed using the Comprehensive assessment of Acceptance and Commitment Therapy Processes (CompACT-10; Golijani-Moghaddam et al., 2023)
Time Frame: From baseline to the end of treatment, up to 16 weeks.

10-item short-form version of the Comprehensive Assessment of Acceptance and Commitment Therapy Processes (CompACT), designed to measure psychological flexibility and its core sub-processes. The minimum value is 0 and the maximum value is 60. A higher score indicates greater level of psychological flexibility.

From baseline to the end of treatment, up to 16 weeks.
Therapeutic alliance assessed using the Session Rating Scale (SRS; Duncan et al., 2003)
Time Frame: Weekly during the therapy intervention, up to 10 weeks.

4-item measure designed to measure the quality of the therapeutic alliance. The minimum value is 0 and the maximum value is 40. A higher score indicates greater therapeutic alliance.

Weekly during the therapy intervention, up to 10 weeks.
Client's perception of therapy sessions assessed using the Helpful Aspects of Therapy (HAT; Llewelyn, 1988)
Time Frame: Weekly during the therapy intervention, up to 10 weeks.

A measure designed to identify specific events that participants found most helpful during the therapy session. The minimum value is 1 and the maximum value is 9 for each scale. A higher score indicates greater helpful impact.

Weekly during the therapy intervention, up to 10 weeks.
Change in client's goals assessed using the Personal Questionnaire (PQ; Elliott et al., 1999)
Time Frame: Weekly during the therapy intervention, up to 10 weeks.

A measure personalised to the participant, identifying problems that the participant would like to work on in therapy. The minimum value is 7 and the maximum value is 91 for each scale. A higher score indicates greater progress towards goals/problem identified at the start of therapy.

Weekly during the therapy intervention, up to 10 weeks.
Adherence to ACT processes measured using the Acceptance and Commitment Therapy Fidelity Measure (ACT-FM; O'Neill et al., 2019)
Time Frame: During the therapy intervention for up to 10 weeks.

A measure of therapist fidelity in delivering Acceptance and Commitment Therapy. The minimum value is 0 and the maximum value is 36 for ACT consistent and ACT inconsistent subscales. A higher score for the ACT consistent subscale indicates adherence to ACT processes.

During the therapy intervention for up to 10 weeks.
Client's perception of therapy intervention and change processes assessed using the Client Change Interview (Elliott et al., 2001)
Time Frame: Within two weeks of end of therapy intervention, at 12 weeks.

A semi-structured interview to explore the mechanism of change.

Within two weeks of end of therapy intervention, at 12 weeks.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Danielle De Boos, ClinPsyD, University of Nottingham

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

August 1, 2027

Study Completion (Estimated)

August 1, 2027

Study Registration Dates

First Submitted

November 5, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The results of the research study will be submitted in partial fulfilment of doctoral thesis in Clinical Psychology. A journal manuscript will be submitted to a peer-reviewed journal and any data submitted will be anonymised. Any published outputs will contain a data availability statement linked to the repository. The full dataset and any special category data will not be publicly available due to participant privacy.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe